San Diego, CA- February 3, 2017 – Objective Capital Partners, a leading M&A investment banking firm focused on transactions for companies with enterprise values up to $500 million, is pleased to announce that David H. Crean, Ph.D., one of its Managing Directors and Head of its Life Sciences and Healthcare practice, will be a guest panelist speaker at Association of Corporate Counsel (ACC) of San Diego on March 2, 2017 from 5:00-6:30 PM. Dr. Crean will be joined by fellow panelists Dennis Doucette, Partner, Corporate & Securities, Practice Group Leader for Procopio, and David Szekeres, Senior Vice President, Business Development, General Counsel and Corporate Secretary for Heron Therapeutics, Inc. The panel will address Current Capital Raising Issues and Strategies for Biotech Companies. The event will be held at the offices of Procopio, Cory, Hargreaves & Savitch LLP, 12544 High Bluff Drive, Suite 300, San Diego, CA 92130.
The panel will include discussions on when is the right time to sell your company or license your product to large strategic partners. For more information about this program, please contact Kim Christianson (kimberly.christianson@procopio.com) at Procopio or http://www.procopio.com/events. This event is complimentary to attend but please note this exclusive roundtable has limited seating. Please register today to secure your spot.
Please note this event is open only to in-house counsel of life sciences companies. Service providers not permitted to attend.
About The Association of Corporate Counsel (ACC)
The Association of Corporate Counsel (ACC) is a global bar association that promotes the common professional and business interests of in-house counsel who work for corporations, associations and other private-sector organizations through information, education, networking opportunities and advocacy initiatives. For more information about ACC, please visit http://www.acc.com.
About Procopio, Cory, Hargreaves & Savitch LLP
Founded in 1946, Procopio is one of the most respected law firms in the Western United States. With more than 150 top attorneys in 40+ practice areas, they are committed to helping you and your business excel. Procopio’s Life Sciences group has decades of experience serving biotechnology, molecular biology and medical device clients, providing counsel on matters involving intellectual property, financing, licensing, and mergers and acquisitions. Their attorneys have extensive Biopharma industry experience combined with a business acumen that uniquely positions our team to provide tremendous value to companies in this sector. They optimize specific strategies for life sciences clients at all stages, from start-ups to large mature companies, in a cost-effective manner that addresses your specific needs. For more information about the firm, please visit http://www.procopio.com/.
About Objective Capital Partners
Objective Capital Partners is a leading M&A investment banking firm whose Principals have collectively engaged in more than 500 successful transactions serving the transaction needs of growth stage and mid-size companies. The executive team has a unique combination of investment banking, private equity, and business ownership experience that enables Objective Capital Partners to provide large enterprise caliber investment banking services to companies with annual revenues up to $500 million. Services include sale transactions, equity and debt capital raises and comprehensive advisory services. The firm uses a proprietary process to work to achieve premium company valuation, strong pricing, and high client satisfaction rates post-sale. The firm’s industry expertise includes: software and hardware technology, life sciences, business services, IT services, healthcare services, biotech, consumer products and specialized manufacturing. Securities and investment banking services are offered through BA Securities, LLC Member FINRA, SIPC. The Principals of Objective Capital are Registered Representatives of BA Securities. Objective Capital Partners and BA Securities are separate and unaffiliated entities. Additional information on Objective Capital Partners is available at www.objectivecp.com.
Disclosure
This news release is for informational purposes only and does not constitute an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities. While the information provided herein is believed to be accurate and reliable, Objective Capital Partners and BA Securities, LLC make no representations or warranties, expressed or implied, as to the accuracy or completeness of such information. All information contained herein is preliminary, limited and subject to completion, correction or amendment. It should not be construed as investment, legal, or tax advice and may not be reproduced or distributed to any person.
# # #
Contact:
David H. Crean, Ph.D.
Managing Director
Objective Capital Partners
3636 Nobel Drive, Suite 160
San Diego, CA 92122
Tel: (858) 461-9490
